Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome.

Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, Rayford W, Yamoah K.

J Urol. 2019 Aug;202(2):247-255. doi: 10.1097/JU.0000000000000193. Epub 2019 Jul 8.

PMID:
31107158
2.

Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer.

Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, Cleveland JL, Park JY, Dhillon J, Yamoah K.

Prostate Cancer Prostatic Dis. 2019 May;22(2):292-302. doi: 10.1038/s41391-018-0103-4. Epub 2018 Oct 26.

3.

Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.

Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, Yamoah K.

Cancer Epidemiol Biomarkers Prev. 2018 Nov;27(11):1376-1383. doi: 10.1158/1055-9965.EPI-18-0369. Epub 2018 Aug 14.

4.

miRNAs associated with prostate cancer risk and progression.

Luu HN, Lin HY, Sørensen KD, Ogunwobi OO, Kumar N, Chornokur G, Phelan C, Jones D, Kidd L, Batra J, Yamoah K, Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park JY, Di Pietro G.

BMC Urol. 2017 Mar 20;17(1):18. doi: 10.1186/s12894-017-0206-6. Review.

5.

Tristetraprolin disables prostate cancer maintenance by impairing proliferation and metabolic function.

Berglund AE, Scott KE, Li W, Yang C, Fernandez MR, Schaub FX, Cleveland JL, Rounbehler RJ.

Oncotarget. 2016 Dec 13;7(50):83462-83475. doi: 10.18632/oncotarget.13128.

6.

CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolin.

Fallahi M, Amelio AL, Cleveland JL, Rounbehler RJ.

PLoS One. 2014 Dec 26;9(12):e115517. doi: 10.1371/journal.pone.0115517. eCollection 2014.

7.

Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.

Doherty JR, Yang C, Scott KE, Cameron MD, Fallahi M, Li W, Hall MA, Amelio AL, Mishra JK, Li F, Tortosa M, Genau HM, Rounbehler RJ, Lu Y, Dang CV, Kumar KG, Butler AA, Bannister TD, Hooper AT, Unsal-Kacmaz K, Roush WR, Cleveland JL.

Cancer Res. 2014 Feb 1;74(3):908-20. doi: 10.1158/0008-5472.CAN-13-2034. Epub 2013 Nov 27.

8.

Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state.

Rounbehler RJ, Fallahi M, Yang C, Steeves MA, Li W, Doherty JR, Schaub FX, Sanduja S, Dixon DA, Blackshear PJ, Cleveland JL.

Cell. 2012 Aug 3;150(3):563-74. doi: 10.1016/j.cell.2012.06.033.

9.

E2F2 suppresses Myc-induced proliferation and tumorigenesis.

Pusapati RV, Weaks RL, Rounbehler RJ, McArthur MJ, Johnson DG.

Mol Carcinog. 2010 Feb;49(2):152-6. doi: 10.1002/mc.20584.

10.

Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma.

Rounbehler RJ, Li W, Hall MA, Yang C, Fallahi M, Cleveland JL.

Cancer Res. 2009 Jan 15;69(2):547-53. doi: 10.1158/0008-5472.CAN-08-2968.

11.

ATM promotes apoptosis and suppresses tumorigenesis in response to Myc.

Pusapati RV, Rounbehler RJ, Hong S, Powers JT, Yan M, Kiguchi K, McArthur MJ, Wong PK, Johnson DG.

Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1446-51. Epub 2006 Jan 23.

12.

Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model.

Rounbehler RJ, Rogers PM, Conti CJ, Johnson DG.

Cancer Res. 2002 Jun 1;62(11):3276-81.

13.

ARF differentially modulates apoptosis induced by E2F1 and Myc.

Russell JL, Powers JT, Rounbehler RJ, Rogers PM, Conti CJ, Johnson DG.

Mol Cell Biol. 2002 Mar;22(5):1360-8.

14.

Myc lacks E2F1's ability to suppress skin carcinogenesis.

Rounbehler RJ, Schneider-Broussard R, Conti CJ, Johnson DG.

Oncogene. 2001 Aug 30;20(38):5341-9.

Supplemental Content

Loading ...
Support Center